Over the last fifty years Parnell has become a leading global veterinary pharmaceutical business marketing products in 15 countries. We have built a fully integrated animal health platform with a strong track record in R&D, clinical science, regulatory processes and with recent FDA accreditation of our sterile manufacturing facility in Sydney, Australia we can bring innovative solutions to market swiftly. Parnell has also developed unique digital technology solutions that integrate with our innovative products to offer veterinarians and animal owners superior solutions to their animal health needs.
Parnell has a market-leading portfolio of products for companion, performance and production animals. We currently market innovative cattle breeding programs as well as osteoarthritis solutions for dogs and horses. In addition we have an impressive pipeline spanning anesthesia, anti-microbials, orthopedics and laminitis.
Parnell has a market-leading portfolio of products for companion, performance and production animals. We currently market innovative cattle breeding programs as well as osteoarthritis solutions for dogs and horses. In addition we have an impressive pipeline spanning anesthesia, anti-microbials, orthopedics and laminitis.
Location: United States, Kansas, Overland Park
Employees: 51-200
Phone: +1 913-274-2100
Founded date: 1986
Investors 3
| Date | Name | Website |
| - | SWK Holdin... | swkhold.co... |
| - | Partners f... | pfgrowth.c... |
| - | DWHP | dwhp.com |
Mentions in press and media 3
| Date | Title | Description |
| 06.01.2023 | Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering | SYDNEY, Jan. 6, 2023 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today announced the extension of the backstopped rights offering to raise gross proceeds of approximately US$4.0 ... |
| 07.12.2022 | Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering | SYDNEY, Dec. 7, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$... |
| 02.12.2022 | Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering | SYDNEY, Dec. 2, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rig... |